• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
    • News & Updates
  • Donate
Home / Patient Corner / Drug Information Sheets / Ibandronate Sodium (Boniva®)

Ibandronate Sodium (Boniva®)

What is Ibandronate Sodium (Boniva®)?

Ibandronate Sodium is used to treat or prevent osteoporosis. Osteoporosis is a disease which causes bones to become thin.  You are at risk for osteoporosis if you are:

Thin Do not exercise
Smoke Drink alcohol often
Caucasian Do not get enough calcium or vitamin D
Going through or past menopause Have a family history of osteoporosis
Take or have taken bone thinning medications like prednisone

How do I take it?

Ibandronate Sodium may be taken by mouth or make be given as an injection. Ibandronate Sodium tablets are taken once a month.  Take the tablet first thing in the morning before you have had anything to eat or drink.  Swallow the tablet with plain water only. Do no chew or crush the tablet. After taking Ibandronate Sodium wait one hour before: eating or drinking, lying down, taking other medications.

Ibandronate Sodium injections are taken every three months. The injection must be administered by a health care professional.

You should not take Ibandronate Sodium if you are pregnant, breast feeding, have kidney problems, or have low blood calcium. If you cannot sit or stand for at least 1 hour, you should not take the tablet form of this medication.

What about side effects?

The most common side effects with the injection are bone, muscle and joint pains, flu like illness and headache. The flu like symptoms generally disappears after 24-48 hours and usually occurs only after the first injection. The most common side effects with the pill are diarrhea, pain in the extremities, and upset stomach.  Less common side effects may be pain or trouble swallowing, heartburn and stomach ulcers.

Rarely patients have reported severe bone, joint and muscle pain that begins from 1 day to one month after starting any bisphosphonate, including Ibandronate Sodium.  Most patients report relief from these symptoms after stopping the medication.

In rare cases some patients have experienced jaw problems when taking bisphosphonates including Ibandronate Sodium.  This included delayed healing and infection.

What about other medications?

Do not take other medications within 1 hour of taking the Ibandronate Sodium pill.

What else should I know?

Contact your doctor if you have any questions about this or any of your medications.  Contact your doctor if you experience any troubling side effects.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Drug Information

  • Drug Information Sheets
  • How to Give a Subcutaneous Injection

List of Treatments

  • Abatacept (Orencia®)
  • Adalimumab (Humira®)
  • Alendronate (Fosamax®)
  • Anakinra (Kineret®)
  • Apremilast (Otezla®)
  • Azathioprine (Imuran®)
  • Certolizumab (Cimzia®)
  • Corticosteroids (i.e. Prednisone)
  • Etanercept (Enbrel®)
  • Febuxostat (Uloric®)
  • Golimumab (Simponi®)
  • Golimumab for infusion (Simponi Aria®)
  • Hyaluronate (Synvisc® & Hyalgan®)
  • Hydroxychloroquine (Plaquenil®)
  • Ibandronate Sodium (Boniva®)
  • Infliximab (Remicade®)
  • Leflunomide (Arava®)
  • Lesinurad/Allopurinol (Duzallo®)
  • Lesinurad (Zurampic®)
  • Methotrexate (Oral)
  • Methotrexate (Injection)
  • Non-Steroidal Anti-inflammatory Drugs
  • Pegloticase (KRYSTEXXA®)
  • Probenecid
  • Risedronate (Actonel®)
  • Rituximab (Rituxan®)
  • Sarilumab (Kevzara®)
  • Secukinumab (Cosentyx®)
  • Sulfasalazine (Azulfidine®)
  • Teriparatide (Forteo®)
  • Tocilizumab (Actemra®)
  • Tofacitinib (Xeljanz®/XeljanzXR®)
  • Ustekinumab (Stelara®) Drug Information Sheet
  • Zolendronic Acid (Reclast®)
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2025 Johns Hopkins Arthritis Center
Patient Privacy